Journal of Clinical Oncology
Articles in this Issue
Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer.
223 Background: p53 immunohistochemistry (IHC) is a prognostic marker in prostate cancer (PCa), but manual scoring by pathologists is time-consuming and p...
ACCEL: [Ac-225]-PSMA-62 phase Ia/Ib/II clinical trial to characterize efficacy, safety, tolerability, and dosimetry in oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
TPS282 Background: Actinium-225 (Ac-225)-based, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) represents a promising treatm...
Bayesian re-analysis: Comparing radical cystectomy with trimodality therapy in patients with muscle invasive bladder cancer.
737 Background: Randomized trials comparing radical cystectomy (RC) and trimodality therapy (TMT) in muscle invasive bladder cancer (MIBC) have not been f...
Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.
244 Background: The addition of androgen receptor pathway inhibitors (ARPI) to androgen deprivation therapy (ADT) has improved survival in patients (pts)...
Preferred treatment regimens for rare genitourinary (GU) malignancies.
780 Background: Rare GU cancers offer a challenge in determining standard of care therapy. Often data is extrapolated from small patient series or other t...
Real-world analysis of 2IR immune response score in urothelial carcinoma (UC).
739 Background: Immune checkpoint inhibition (ICI) is often used to treat UC, however many patients (pts) exhibit resistance. Using bulk RNA sequencing of...
Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT).
66 Background: In the pivotal phase 3 ARASENS trial, patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide in combi...
Patterns of next-generation sequencing and associated next-line systemic therapy use in metastatic prostate cancer.
105 Background: Next-generation sequencing (NGS) testing is used for prognostication and to guide treatment choice in metastatic prostate cancer (mPC). Wh...
Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.
201 Background: VOPis an algorithm that predicts the cellular origin of variants, currently available on FoundationOneLiquid CDx (F1LCDx) for research use...
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
438 Background: In the randomized, double-blind, phase 3 COSMIC-313 study (NCT03937219), C+N+I significantly improved PFS compared with N+I in first-line...
Tumor necrosis factor alpha signaling activity and NCCN risk, adverse pathology, and progression during active surveillance in prostate cancer.
415 Background: Elevated serum levels of tumor necrosis factor alpha (TNF-α) are characteristic of chronic inflammatory conditions and advanced prostate c...
Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.
768 Background: The gut microbiome has emerged as a critical factor influencing the efficacy and toxicity of cancer treatments. In bladder cancer, variati...
Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.
308 Background: NRG/RTOG 0126 and SAKK 09/10 were phase III randomized trials examining whether higher dose resulted in better response/outcomes in PCa pa...
Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study.
673 Background: Radical nephroureterectomy (RNU) bears a high recurrence risk. Thus, postoperative treatment is necessary for upper urinary tract urotheli...
NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment.
TPS890 Background: Neoadjuvant therapy (NAT) followed by radical cystectomy (RC) is the standard of care for muscle-invasive bladder cancer (MIBC). Approx...
Evaluating the spectrum of disease within Gleason grade group 3: Results from a large institutional cohort.
361 Background: A biopsy diagnosis of Gleason Grade Group (GG) 3 prostate cancer (PCa), also known as Gleason 4+3, automatically risk stratifies patients...
Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer.
832 Background: Intravesical Bacillus Calmette-Guerin (BCG) is the guideline-recommended therapy for high-risk non-muscle invasive bladder cancer (HR-NMIB...
Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study.
726 Background: Currently, the efficacy of cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is unsatisfied...
ctDNA characterization in mCRPC patients with pathogenic germline variants.
247 Background: Approximately 10% to 15% of men with metastatic castration-resistant prostate cancer (mCRPC) harbor germline mutations. Circulating tumor-...
Comparing quality of life in prostate cancer patients: Continuous vs. intermittent androgen deprivation therapy—A systematic review and meta-analysis.
117 Background: Intermittent (i) and continuous (c) androgen deprivation therapy (ADT) not only play a critical role in managing prostate cancer (PC) but...
Evaluating worldwide disparities in bladder cancer clinical trial availability.
672 Background: Bladder cancer (BC) poses a disproportionate burden on low- and middle-income countries (BJUI, 2017), yet...
A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC).
806 Background: Approximately 75% of patients with non-muscle invasive bladder cancer (NMIBC) treated with transurethral resection (TUR) followed by intra...
Germline correlates of clinical outcomes in aggressive prostate cancer subtypes treated with radiation therapy.
418 Background: Research on the genetic profile of cribriform pattern (CP) and intraductal carcinoma (IDC) subtypes of aggressive prostate cancer (PCa) is...
Use of integrated multi-omics profiling in renal cell carcinoma to identify molecular subtypes and associated clinical outcomes and therapeutic vulnerabilities.
588 Background: Although histologically defined subtypes exist, renal cell carcinoma (RCC) is a heterogenous disease, resulting in various treatment outco...
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).
TPS904 Background: Activating FGFR3 gene alterations have been identified in up to 20% of advanced/metastatic urothelial cancers (...